📊 SYRA Key Takeaways
Is Syra Health Corp (SYRA) a Good Investment?
Syra Health is unprofitable with negative operating cash flow and zero revenue growth, indicating a stagnant business model struggling to scale. While the company shows improving profitability trends (+76.2% YoY net income improvement) and maintains strong liquidity (4.06x current ratio) with no debt, the operational cash burn rate (~$448K annually) erodes the cash runway given the small revenue base of $7.2M.
Why Buy Syra Health Corp Stock? SYRA Key Strengths
- Excellent liquidity position with 4.06x current and quick ratios, providing short-term financial stability
- Significant cash reserves of $1.6M representing 57% of total assets, providing runway for operational turnaround
- Zero long-term debt and low leverage (0.0x debt-to-equity), eliminating refinancing and bankruptcy risks
- Improving profitability trajectory with net income +76.2% YoY and EPS improving +84% YoY
SYRA Stock Risks: Syra Health Corp Investment Risks
- Company is operationally unprofitable with negative operating income (-$904.3K) and net margin of -12.4%
- Negative operating cash flow (-$447.7K) indicates cash burn despite positive cash balance, limiting sustainability
- Flat revenue growth (0.0% YoY) with only $7.2M in revenue demonstrates zero business expansion or market traction
- Negative returns on equity (-42.7%) and assets (-32.3%) showing capital is destroying rather than creating value
- Very small company with limited scale in competitive employment services sector, which typically operates on thin margins
- Minimal insider activity (1 Form 4 filing in 90 days) suggests lack of management confidence
Key Metrics to Watch
- Quarterly revenue growth trend - must achieve positive YoY growth to validate business model
- Operating cash flow - critical to watch if negative cash burn continues and remaining runway
- Path to operating profitability and EBITDA breakeven point
- Cash balance levels relative to quarterly burn rate
- Form 4 insider transactions - increased buying would signal management confidence in turnaround
Syra Health Corp (SYRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.06x current ratio provides a solid financial cushion.
SYRA Profit Margin, ROE & Profitability Analysis
SYRA vs Services Sector: How Syra Health Corp Compares
How Syra Health Corp compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Syra Health Corp Stock Overvalued? SYRA Valuation Analysis 2026
Based on fundamental analysis, Syra Health Corp has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Syra Health Corp Balance Sheet: SYRA Debt, Cash & Liquidity
SYRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Syra Health Corp's revenue has grown significantly by 42% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.50 indicates the company is currently unprofitable.
SYRA Revenue Growth, EPS Growth & YoY Performance
SYRA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.7M | -$63.6K | $-0.02 |
| Q2 2025 | $1.9M | -$63.6K | $-0.01 |
| Q1 2025 | $1.8M | -$472.3K | $-0.04 |
| Q3 2024 | $1.6M | -$354.4K | $-0.06 |
| Q2 2024 | $979.2K | -$785.9K | $-0.18 |
| Q1 2024 | $1.2M | -$785.9K | $-0.18 |
| Q3 2023 | $1.5M | -$354.4K | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Syra Health Corp Dividends, Buybacks & Capital Allocation
SYRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Syra Health Corp (CIK: 0001922335)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SYRA
What is the AI rating for SYRA?
Syra Health Corp (SYRA) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SYRA's key strengths?
Claude: Excellent liquidity position with 4.06x current and quick ratios, providing short-term financial stability. Significant cash reserves of $1.6M representing 57% of total assets, providing runway for operational turnaround.
What are the risks of investing in SYRA?
Claude: Company is operationally unprofitable with negative operating income (-$904.3K) and net margin of -12.4%. Negative operating cash flow (-$447.7K) indicates cash burn despite positive cash balance, limiting sustainability.
What is SYRA's revenue and growth?
Syra Health Corp reported revenue of $7.2M.
Does SYRA pay dividends?
Syra Health Corp does not currently pay dividends.
Where can I find SYRA SEC filings?
Official SEC filings for Syra Health Corp (CIK: 0001922335) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SYRA's EPS?
Syra Health Corp has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SYRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Syra Health Corp has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SYRA stock overvalued or undervalued?
Valuation metrics for SYRA: ROE of -42.7% (sector avg: 16%), net margin of -12.4% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy SYRA stock in 2026?
Our dual AI analysis gives Syra Health Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SYRA's free cash flow?
Syra Health Corp's operating cash flow is $-447.7K, with capital expenditures of $107.0. FCF margin is -6.2%.
How does SYRA compare to other Services stocks?
Vs Services sector averages: Net margin -12.4% (avg: 10%), ROE -42.7% (avg: 16%), current ratio 4.06 (avg: 1.5).